Comparative evaluation of antifungal susceptibility testing methods for Rhizopus species isolates

Document Type : Short Communication


Department of Microbiology, King George's medical university, Lucknow, India


Background and Purpose:The mainstay of treatment for COVID-19-associated mucormycosis was liposomal Amphotericin B. Other antifungal agents such as posaconazole and isavuconazole were also used. CLSI M38 A3 and EUCAST recommend broth microdilution method for Antifungal susceptibility testing. We, therefore, conducted this study to see what potency and zone diameters correlate with the gold standard broth microdilution method.
Materials and Methods: All the isolates were identified by MALDI-TOF. A total of 127 isolates of 83 Rhizopus oryzae complex and 44 isolates of Rhizopus microsporus complex were selected. Anti-fungal susceptibility testing by Disc diffusion and E-test was done on non-supplemented Mueller Hinton Agar and was compared with the CLSI broth microdilution method of Anti-fungal susceptibility testing.
Results: Percentage agreement was found to be more in the case of the E test than Disc Diffusion method. In the case of Rhizopus oryzae, posaconazole had 98.79% agreement with broth microdilution followed by Isavuconazole (97.59%), Itraconazole (96.38%), and Amphotericin B (91.56%).
Conclusion: Disc diffusion correlates well with broth microdilution (BMD), although its correlation is weaker when compared to the E test. The effective concentration of AMB discs for antifungal susceptibility testing (AFST) depends on the specific Rhizopus species.


Main Subjects

  1. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-69.
  2. Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):523.
  3. Asrani P, Eapen MS, Hassan MI, Sohal SS. Implications of the second wave of COVID-19 in India. Lancet Respir Med. 2021;9(9):e93-4.
  4. Ranjan R, Sharma A, Verma MK. Characterization of the Second Wave of COVID-19 in India. MedRxiv. 2021:2021-04.
  5. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-21.
  6. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73:919-34.
  7. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008;73(5):538-46.
  8. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, Ellis D, Pfaller MA, Messer S, Rinaldi M, Fothergill A, Gibbs DL, Wang A. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol. 2007;45(6):1811-20.
  9. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis. 1997;24(2):235-47.
  10. Gupta P, Malhotra HS, Saxena P, Singh R, Shukla D, Hasan MS, Verma V, Banerjee G, Puri B, Dandu H. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis. J Investig Med. 2022;70(4):914-8.
  11. Salas V, Pastor FJ, Calvo E, Alvarez E, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J. In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole. Antimicrob Agents Chemother. 2012;56(5):2246-50.

     12. Chowdhary A, Singh PK, Kathuria S, Hagen F, Meis JF. Comparison of the EUCAST and CLSI broth  microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified Mucorales species. Antimicrob Agents Chemother. 2015;59(12):7882-7. 

Volume 9, Issue 4
December 2023
Pages 47-50
  • Receive Date: 13 November 2023
  • Revise Date: 07 January 2024
  • Accept Date: 08 January 2024
  • First Publish Date: 08 January 2024
  • Publish Date: 01 December 2024